Integumentary System Case Studies

Each of these mini-case studies extend topics in the minilectures to a clinical presentation. Feel free to read as many as you like!

PATIENT 1: Sarah Kowalski, 45 – Atopic Dermatitis (Eczema)

Initial Presentation:

Sarah has had “sensitive skin” her whole life, but it’s gotten significantly worse in the past 5 years. She has red, dry, intensely itchy patches on the inner creases of her elbows, behind her knees, and on her neckNarrow region just below the head; common fracture site.. The skinThe body’s largest organ, providing protection and regulation. is thickened and leathery from years of scratching (lichenification). She wakes up at night scratching unconsciously and sometimes scratches until she bleeds. “Winter is the worst—my skin just cracks and weeps,” she says, showing fissures on her hands. Sarah has a history of childhood asthmaA chronic condition characterized by airway inflammation, narrowing, and excessive mucus production, and seasonal allergies. She’s tried countless lotions and creams but finds only temporary relief. She’s frustrated and exhausted.

What’s Happening:

Sarah’s epidermal barrier is broken. She likely has a genetic mutationA change in DNA sequence that can affect gene function. in filaggrin, the protein that helps keratinocytesThe most abundant cells in the epidermis, responsible for producing keratin. produce strong, waterproof keratinA strong, fibrous protein that forms the structure of skin, hair, and nails.. Her stratum corneumThe outermost layer of the epidermis, consisting of dead, keratinized cells. is defective—it can’t hold moisture in or keep allergens out. The keratinocyte “conveyor belt” is moving at normal speed (28 days from stratum basaleThe deepest layer of the epidermis, where new skin cells are formed. to stratum corneum), but the cellsThe basic structural and functional units of life. being produced are fundamentally flawed. Imagine trying to waterproof your basement with a bucket full of holes—that’s Sarah’s stratum corneum. Water escapes, the skin dries out, cracks form, and allergens penetrate, triggering immune reactions.

Comparison to Psoriasis:

Sarah’s conveyor belt runs at normal speed but produces defective products. Marcus’s runs 7 times too fast but produces relatively normal cells—they just don’t have time to mature. Sarah’s skin is thin and leaky; Marcus’s is thick and scaly. Sarah’s problem is in the stratum corneum’s barrier function; Marcus’s is in the stratum basale’s proliferation rate. Sarah has intense itching; Marcus has minimal itch. Sarah’s inflammation is a response to barrier failure; Marcus’s is autoimmune-driven.

Diagnostic Tests:

• Clinical diagnosis based on history (childhood atopic disease), distribution (flexural areas), and appearance (lichenification)
• Patch testing offered to rule out contact allergies—negative
• Skin biopsy (optional): Would show spongiosis (fluid between epidermal cells) and inflammatory infiltrate

Treatment Journey:

Month 1-2: Started aggressive moisturization regimen—thick ointments (petroleum jelly, CeraVe Healing Ointment) applied multiple times daily, especially after bathing while skin is still damp. This is barrier repair—compensating for the defective keratin. Also prescribed triamcinolone 0.1% ointment (mid-potency topical corticosteroid) for active flares, applied twice daily for 2 weeks then tapered. Sarah sees 40% improvement but still has breakthrough itching.

Month 3-5: Added tacrolimus 0.1% ointment (Protopic, a calcineurin inhibitor) for face and neck, where long-term steroid use can cause skin thinning. Tacrolimus suppresses T-cell activation without the side effects of steroids. Sarah also starts taking antihistamines (cetirizine) at night to reduce itching and help her sleep.

Month 6: Sarah has a major flare during a stressful period at work. Her provider prescribes a short course of oral prednisone (40mg daily for 5 days, then taper) to get inflammation under control quickly. This works, but the provider emphasizes this is not a long-term solution—oral steroids have significant side effects.

Month 7-9: Provider refers Sarah to dermatology for consideration of dupilumab (Dupixent), a biologic medication. Dupixent is a monoclonal antibody that blocks IL-4 and IL-13, key inflammatory cytokines in atopic dermatitis. It’s given as a subcutaneous injection every 2 weeks. Insurance requires prior authorization and documentation of failed topical treatments. After approval, Sarah starts Dupixent.

Month 12: Sarah’s skin is 75% clear. She still uses moisturizers religiously and occasional topical steroids for small flares, but the Dupixent has dramatically reduced baseline inflammation. “I slept through the night without scratching for the first time in years,” she reports, tearfully. Her neck no longer looks like “alligator skin.” She can wear short sleeves without feeling self-conscious.

Emotional Impact:

Sarah describes eczema as “exhausting and humiliating.” The constant itching disrupted her sleep, affecting her mood and work performance. Visible rashes on her neck made her feel “dirty” even though eczema isn’t contagious or due to poor hygiene. She avoided swimming, short sleeves, and social situations where people might see her skin. “People stare. Kids ask what’s wrong with you. It wears you down.” Treatment wasn’t just about clearing her skin—it was about reclaiming sleep, comfort, and dignity.

Long-term Management:

Sarah will likely need Dupixent indefinitely. She understands her barrier is genetically compromised, so moisturization is lifelong. She identifies her triggers—stress, dry winter air, certain fabrics—and adjusts her environment. She’s learned to advocate for herself, explaining to curious strangers, “It’s atopic dermatitis, a genetic skin condition. It’s not contagious.”

---

PATIENT 2: Marcus Thibault, 52 – Psoriasis Vulgaris

Initial Presentation:

Marcus has had thick, scaly patches on his elbows and knees for about 8 years, but he initially ignored them because they didn’t itch much. Over the past year, the patches have spread to his scalp, lower back, and behind his ears. The plaques are well-defined, raised, and covered with thick silvery-white scales. When he scratches them, they bleed easily (Auspitz sign). Marcus also mentions his nailsHard, keratinized structures that protect the fingertips and enhance fine motor skills. have small pits and his right knee has been stiff and swollen for months—his doctor suspects psoriatic arthritis. “My dad had this too,” Marcus says. “He called it his ‘lizard skin.’ I thought it was just dry skin, but lotion doesn’t help.”

What’s Happening:

Marcus’s keratinocyte conveyor belt is in hyperdrive. His immune system—specifically, his T-cells—has mistakenly identified skin cells as foreign invaders and is attacking them. This autoimmune attack releases inflammatory cytokines (TNF-α, IL-17, IL-23) that tell the stem cells in the stratum basale to divide rapidly. Normal turnover is 28 days; Marcus’s is 3-4 days. Keratinocytes are being shoved to the surface before they can mature, flatten, and die properly. They pile up in thick, disorganized layers in the stratum corneum. Those silvery scales? Immature, incompletely keratinized cells stacked on top of each other.

Comparison to Sarah (Eczema):

Marcus’s conveyor belt is too fast (3-4 days vs. normal 28 days). Sarah’s is normal speed but makes broken products. Marcus has thick, raised plaques; Sarah has thin, leaky, dry patches. Marcus’s lesions are on extensor surfaces (outer elbows, outer knees) where friction occurs; Sarah’s are on flexural surfaces (inner elbows, behind knees) where moisture traps. Marcus has minimal itch; Sarah has intense itch. Marcus’s problem is hyperproliferation driven by autoimmunity; Sarah’s is barrier dysfunction driven by defective keratin.

Diagnostic Tests:

• Clinical diagnosis based on appearance (well-demarcated plaques with silvery scale) and distribution (extensor surfaces, scalp)
• Skin biopsy (done to confirm): Showed acanthosis (thickened epidermisThe outermost layer of the skin, made of stratified squamous epithelium.), parakeratosis (nucleiClusters of neurons in the CNS responsible for processing information. retained in stratum corneum—sign of rapid turnover), and inflammatory infiltrate
• X-rays of knee: Early signsObjective clinical findings observable by a provider (e.g., edema, fever). of psoriatic arthritis (joint space narrowing, periosteal reaction)

Treatment Journey:

Month 1-3: Started with topical therapy—clobetasol 0.05% ointment (high-potency corticosteroid) applied twice daily to plaques, plus calcipotriene 0.005% ointment (vitamin D analog) which slows keratinocyte proliferation. Also prescribed coal tar shampoo for scalp psoriasis. Marcus sees 30% improvement but still has extensive plaques and the scalp lesions are stubborn.

Month 4-6: Added narrowband UVB phototherapy (light therapy) 3 times per week at dermatology clinic. UVB slows keratinocyte division and has immunosuppressive effects. After 12 weeks of phototherapy, Marcus is about 60% clear, but the time commitment (driving to clinic 3x/week) is unsustainable with his work schedule.

Month 7: Dermatologist discusses systemic therapy options. Given Marcus’s psoriatic arthritis, they recommend a biologic medication that will treat both skin and joints. Marcus starts adalimumab (Humira), a TNF-α inhibitor, given as a subcutaneous injection every 2 weeks. TNF-α is a major inflammatory cytokine driving both psoriasis and psoriatic arthritis. Blocking it should slow the autoimmune attack.

Month 10-12: Marcus’s skin is 80% clear. The thick plaques on his elbows have flattened dramatically. His scalp is almost completely clear. Best of all, his knee pain and stiffness have improved significantly—he can climb stairs without wincing. “I didn’t realize how much the joint pain was affecting me until it was gone,” he says. He continues topical calcipotriene for small stubborn spots but has stopped the high-potency steroids.

Future Adjustments:

At month 18, Marcus’s psoriasis starts breaking through the adalimumab. His dermatologist switches him to guselkumab (Tremfya), an IL-23 inhibitor—a newer class of biologic with potentially better long-term efficacy. This is given every 8 weeks after loading doses. Marcus responds well.

Emotional Impact:

Marcus initially downplayed his psoriasis—”It’s just rough skin, who cares?” But as it spread and became more visible, he felt increasing self-consciousness. “People think you have a contagious rash. They don’t want to shake your hand. A barber once refused to cut my hair because of my scalp.” The joint pain made him feel old and limited his activities. Treatment restored not just his skin but his mobility and social confidence. He’s learned psoriasis is an autoimmune disease, not poor hygiene, and he’s not ashamed to explain that to others.

Long-term Management:

Marcus will need lifelong treatment. Psoriasis is a chronic autoimmune condition. He’ll stay on biologic therapy indefinitely, with monitoring bloodwork every 6 months (biologics can affect liverA large organ that produces bile, detoxifies blood, and stores nutrients. function and increase infection risk). He’s accepted this—”One injection every 8 weeks is a small price to pay for clear skin and pain-free joints.”

---

---

PATIENT 3: Alicia Morales, 34 – Vitiligo

Initial Presentation:

Alicia noticed a small white patch on the back of her left hand about 2 years ago. She assumed it was a fungal infection or sun damage and tried antifungal creams with no effect. The patch gradually grew, and new patches appeared on her other hand, around her mouthThe opening of the digestive tract where food enters and mastication begins., and near her eyes. The borders are sharp and clearly demarcated. Her skin is otherwise healthy—no itching, no pain, no texture changes—just complete loss of pigment in affected areas. Alicia has medium-brown skin (Fitzpatrick type IV), so the white patches are strikingly visible. She’s devastated. “I feel like my skin is disappearing. I don’t recognize myself in the mirror anymore,” she says, crying.

What’s Happening:

Alicia’s melanocytesCells in the stratum basale that produce melanin, the pigment responsible for skin color. are being destroyed by her own immune system. Vitiligo is an autoimmune condition where T-cells attack and kill melanocytes in the stratum basale. Once the melanocytes are gone, keratinocytes in that area no longer receive melaninA brown-black pigment made by melanocytes in the stratum basal and given to keratinocytes as melanos. The keratinocytes are still there—the epidermis is intact—but without melanin, the skin appears white. The melanocyte conveyor belt analogy: The factory workers (melanocytes) who package pigment into the products (keratinocytes) have been eliminated, so all the products coming off the line are colorless.

Comparison to Grace (Melasma):

Alicia has lost melanocytes (destroyed by autoimmunity); Grace has overactive melanocytes (stimulated by hormones). Alicia’s patches are completely depigmented (white); Grace’s are hyperpigmented (brown). Alicia’s borders are sharp and well-defined; Grace’s are irregular and blotchy. Alicia’s condition is progressive and unpredictable; Grace’s is often triggered by pregnancy/hormones and may fade postpartum. Treatment for Alicia tries to restore pigment or stop progression; treatment for Grace tries to reduce pigment.

Diagnostic Tests:

• Clinical diagnosis based on appearance (depigmented macules with sharp borders)
• Wood’s lamp examination: UV light makes vitiligo patches fluorescent bright white, confirming loss of pigment
• Thyroid function tests (TSH, anti-thyroid antibodies): Vitiligo is associated with other autoimmune diseases like Hashimoto’s thyroiditis and Graves’ disease—Alicia’s thyroid function is normal
• Skin biopsy (optional): Would show absence of melanocytes in affected areas

Treatment Journey:

Month 1-3: Started with tacrolimus 0.1% ointment (calcineurin inhibitor) applied twice daily to patches. This suppresses the local immune attack on melanocytes. Also prescribed narrowband UVB phototherapy 3 times per week. UVB can stimulate any remaining melanocytes to proliferate and migrate into depigmented areas. Progress is slow—maybe 10% repigmentation on her hands after 3 months.

Month 4-6: Dermatologist adds excimer laser therapy (targeted UVB) to her facial patches—this delivers higher doses of UVB to specific areas. Alicia sees some repigmentation around her mouth, but the patches around her eyes show minimal improvement. She’s discouraged by the slow progress and time commitment.

Month 7-9: Offered a trial of oral ruxolitinib (Jakafi), a JAK inhibitor, which has shown promise in vitiligo by blocking the inflammatory signals that drive melanocyte destruction. This is off-label use (ruxolitinib is FDA-approved for other conditions, but recently FDA approved a topical JAK inhibitor, ruxolitinib cream/Opzelura, specifically for vitiligo). Alicia starts topical ruxolitinib cream applied twice daily. Over 3 months, she sees noticeable repigmentation on her hands—maybe 30-40% color return.

Month 12: Alicia has achieved about 50% repigmentation on her hands and around her mouth. The patches near her eyes remain mostly depigmented. Her dermatologist explains that facial vitiligo, especially periocular (around eyes), is harder to treat. Alicia is offered depigmentation therapy (using monobenzone cream to remove remaining pigment and create uniform skin tone) for her hands if repigmentation stalls, but she declines for now—she wants to keep trying.

Counseling and Support:

Alicia joins a vitiligo support group and connects with others who understand the emotional impact. She learns about cosmetic camouflage—special makeup designed to cover vitiligo—and finds this helpful for important events. Her dermatologist emphasizes sun protection: Depigmented skin has zero melanin, meaning zero UV protection. Alicia must use SPF 50+ sunscreen and wear protective clothing to prevent burns and skin cancerAbnormal growth of skin cells, often due to UV exposure. in affected areas.

Emotional Impact:

Alicia describes vitiligo as an “identity crisis.” Her appearance changed in ways she couldn’t control, and people stared or asked intrusive questions (“What happened to your skin?”). She felt like her body was betraying her. “Vitiligo is isolating. People don’t understand that it’s autoimmune—they think it’s contagious or a burn or something I did wrong.” She’s struggled with anxiety and depression. Connecting with the vitiligo community and seeing models and public figures with vitiligo (like Winnie Harlow) helped her reframe her condition. “I’m learning to see it as part of who I am, not a flaw.”

Long-term Management:

Vitiligo is unpredictable—it may stabilize, continue spreading, or even spontaneously repigment (rare). Alicia will continue topical treatment and phototherapy for now. If her vitiligo stabilizes and she’s satisfied with repigmentation, she might consider melanocyte transplant surgery (grafting pigmented skin onto depigmented areas)—this is experimental but showing promise. She’s accepted that she may never fully repigment, and she’s working on self-acceptance while continuing treatment.

---

PATIENT 4: Grace Andersen, 29 – Melasma

Initial Presentation:

Grace developed brown patches on her cheeks, upper lip, and forehead during her second pregnancy 2 years ago. She assumed it would fade after delivery like her first pregnancy, but it hasn’t. The patches are symmetrical, irregularly shaped, and range from light to dark brown. They’re more noticeable in summer and after sun exposure. Grace is frustrated and embarrassed. “I feel like I have a dirt mustache. I scrub my face thinking it’ll come off, but it doesn’t. People ask if I’m tired or sick because of the dark patches. I just want my old skin back.”

What’s Happening:

Grace’s melanocytes are overproducing melanin. Melasma is triggered by hormonal changes (pregnancy, birth control, hormone replacement therapy) combined with UV exposure and genetic predisposition. Estrogen and progesteroneA hormone that supports pregnancy and regulates the menstrual cycle. stimulate melanocytes to make more melanin. UV radiation amplifies this effect. The melanocytes aren’t being destroyed—they’re working overtime, pumping out excessive melanin that gets deposited in the epidermis and sometimes the dermisThe thick inner layer of the skin that contains blood vessels, nerves, and connective tissue.. It’s like the melanocyte factory is running a double shift, producing way more pigment than the keratinocytes need.

Comparison to Alicia (Vitiligo):

Grace’s melanocytes are overactive and overproducing; Alicia’s are absent (destroyed). Grace has hyperpigmentation (too much melanin); Alicia has depigmentation (no melanin). Grace’s patches are brown with irregular borders; Alicia’s are white with sharp borders. Grace’s was triggered by hormones (pregnancy); Alicia’s is autoimmune. Treatment for Grace aims to reduce melanin production; treatment for Alicia aims to restore melanocytes or accept depigmentation.

Diagnostic Tests:

• Clinical diagnosis based on appearance (symmetric facial hyperpigmentation) and history (onset during pregnancy)
• Wood’s lamp examination: Helps determine if melanin is epidermal (enhances under Wood’s lamp, better prognosis) or dermal (doesn’t enhance, harder to treat). Grace’s is primarily epidermal with some dermal component.
• No biopsy needed (diagnosis is clinical)

Treatment Journey:

Month 1-3: Started with triple combination cream (hydroquinone 4% + tretinoin 0.05% + fluocinolone 0.01%) applied nightly. This is considered gold-standard for melasma. Hydroquinone inhibits tyrosinase, the enzyme that makes melanin. Tretinoin increases cell turnover, helping to shed pigmented cells. Fluocinolone is a mild steroid that reduces inflammation. Grace also starts strict daily sunscreen (SPF 50+, zinc oxide-based) and wears a wide-brimmed hat outdoors. After 3 months, her patches are about 30% lighter but still visible.

Month 4-6: Continues triple cream but adds tranexamic acidA substance that releases hydrogen ions (H⁺) in solution. 250mg orally twice daily. Tranexamic acid is a medication originally used to control bleeding, but it’s been found to reduce melasma by interfering with melanin synthesis. After 2 more months, Grace sees additional lightening—maybe 50% improvement overall.

Month 7: Grace wants faster results for an upcoming wedding. Her dermatologist offers chemical peels (glycolic acid 30%) every 2-4 weeks for 3 sessions. The peels exfoliateThe shedding of dead skin cells from the surface. the pigmented epidermal cells. Combined with her topical regimen, this provides additional lightening. Grace is about 70% improved by the wedding.

Month 10: Grace stops hydroquinone (it shouldn’t be used long-term—risk of ochronosis, a paradoxical darkening). She switches to azelaic acid 15% gel for maintenance, which also inhibits tyrosinase but is safer for long-term use. She continues tranexamic acid and daily sunscreen religiously.

Setbacks:

At month 14, Grace goes on a beach vacation and doesn’t reapply sunscreen frequently enough. Her melasma darkens significantly within days. She’s devastated. Her dermatologist reminds her: “Melasma is chronic and sun-sensitive. One day of sun can undo months of treatment.” Grace restarts the triple cream for 8 weeks and learns her lesson about sun protection.

Emotional Impact:

Grace felt “marked” by her pregnancies. “I love my kids, but I hate that my skin changed permanently. It feels unfair—pregnancy already changes your body so much, and then this doesn’t go away.” She spent significant money on makeup to cover the patches before seeking treatment. She felt judged—”People assume you don’t take care of yourself or you’re not using good skincare. But this is hormonal. I didn’t do anything wrong.” Treatment gave her hope, but the chronic nature of melasma (it can recur with sun exposure, future pregnancies, or hormone changes) is frustrating.

Long-term Management:

Grace will need lifelong sun protection—sunscreen, hats, avoiding peak sun hours. Melasma can return with any hormonal change (like if she has another child or starts birth control). She’s on maintenance therapy with azelaic acid and tranexamic acid. She’s learned to think of melasma like a chronic condition that can be managed but not cured. “I’ve accepted it’s part of my life now. I can keep it under control, but I have to be vigilant.”

---

---

PATIENT 5: David Yamamoto, 67 – Acute 2nd Degree Burn

Initial Presentation:

David was cooking and accidentally grabbed a hot cast-iron pan handle 3 days ago. He has a 2nd degree partial-thickness burnAnother term for a second-degree burn, affecting the epidermis and part of the dermis. on his right forearm—about 4 inches long and 2 inches wide. The area is red, swollen, and has several intact blisters filled with clear fluid. He’s been running it under cold waterThe universal solvent essential for life. and applying aloe vera, but it’s very painful. He’s worried about scarring because the burn is on his visible forearm. “I’m retired but I still play tennis twice a week. Will I be able to use my arm normally? Will it heal properly at my age?”

What’s Happening:

David’s burn has destroyed the entire epidermis and the superficialNear the surface of the body. portion of the dermis. The subpapillary plexusA network of blood capillaries that vascularize the papillary layer of the dermis of skin. Loops ext (the superficial network of blood vessels in the dermis) is damaged, but the cutaneous plexusA network of blood capillaries that vascularizes the hypodermis/dermis border of skin. (the deeper network) is intact. This is critical—the deeper vessels will supply oxygen and nutrients for healing. Stem cells in the stratum basale, hair folliclesStructures in the ovaries that contain developing oocytes., and sweat glands (if they survived in the deeper dermis) will regenerate the epidermis. David is currently in the inflammatory phase (days 0-3): His body has formed a fibrinAn insoluble protein that forms the mesh of blood clots. clot, neutrophils are cleaning debris, and inflammation is in full swing (hence the redness and swelling).

Comparison to Monica (Chronic Diabetic Ulcer):

David’s wound is acute (single traumatic event) with intact deeper vasculature; Monica’s is chronic (ongoing pressureThe force exerted by gases in the respiratory system, affecting airflow and gas exchange./poor circulation) with compromised vasculature. David’s wound will progress through all three healing phases if infection is prevented; Monica’s is stuck in the inflammatory phase due to diabetes and ischemia. David is older but otherwise healthy; Monica has multiple comorbidities (diabetes, obesity, venous insufficiency). David’s burn will heal in 3-4 weeks; Monica’s ulcer has been present for 6+ months.

Treatment Journey:

Days 3-5 (Inflammatory Phase): David is instructed to gently clean the burn daily with mild soap and water. Do NOT rupture the blisters—they’re a natural sterile dressing. Apply silver sulfadiazine cream (antimicrobial) and cover with a non-adherent dressing (petroleum-impregnated gauze). Take ibuprofen for pain and inflammation. Keep the burn elevated to reduce swelling.

Days 6-10 (Early Proliferative Phase): The blisters have ruptured on their own. Underneath, pink granulation tissue is forming—David can see the bumpy, fragile new tissue. Keratinocytes are migrating from the wound edges and from surviving hair follicles in the deeper dermis, beginning to resurface the burn. Silver sulfadiazine is discontinued (it can slow re-epithelialization). He switches to petroleum jelly or Aquaphor to keep the wound moist—moist wound healing is faster and results in less scarring. Non-adherent dressing continues.

Days 11-21 (Proliferative Phase): The wound is about 80% re-epithelialized. The new epidermis is thin, pink, and fragile but intact. Granulation tissue beneath is being remodeled into scar tissue. David is instructed to keep the area protected from sun (new epidermis has no melanocytes yet) and continue moisturizing. He can start gentle range-of-motion exercises to prevent stiffness.

Weeks 4-8 (Early Remodeling Phase): The burn is completely re-epithelialized. It’s pink/red due to the new blood vessels in the granulation tissue. The scar is slightly raised. David starts using silicone gel sheets (applied daily for 12+ hours) to flatten and soften the scar. He continues sun protection—SPF 50+ sunscreen, long sleeves outdoors.

Months 3-12 (Remodeling Phase): The scar gradually fades from red to pink to pale. It flattens. David can see some texture differences compared to normal skin, but overall the healing is excellent. At 6 months, he’s back to playing tennis with full arm function. At 1 year, the scar is barely noticeable unless you know where to look—it’s slightly lighter than surrounding skin and smoother (no hair or pores).

Complications Avoided:

David did NOT develop infection (thanks to proper cleaning and silver sulfadiazine). He did NOT develop contracture (scar tissue tightening, restricting movementA fundamental property of life involving motion of the body or its parts.) because the burn wasn’t over a joint and he did range-of-motion exercises. He did NOT develop hypertrophic scarring, possibly helped by silicone sheets and sun protection.

Emotional Impact:

David was initially anxious about his age affecting healing. “I’ve heard older people don’t heal as well. I was worried I’d lose function in my arm.” His healthcare provider reassured him that while healing is slightly slower in older adults, he’s otherwise healthy (no diabetes, good nutrition, doesn’t smoke), which are more important factors. Seeing the wound progress through the phases as expected was reassuring. “Once I understood what was supposed to happen—the granulation tissue, the pink new skin—I stopped panicking every time it looked different.”

Long-term Outcome:

At 18 months post-burn, David has a well-healed scar with excellent function. It’s lighter than his surrounding skin (no melanocytes in scar tissue) and slightly smoother (no hair follicles or sweat glands), but it doesn’t limit his activities. He’s learned the importance of sun protection on scars and shares his story with other burn patients to give them hope.

---

PATIENT 6: Monica Williams, 55 – Chronic Diabetic Venous Leg Ulcer

Initial Presentation:

Monica has had a non-healing wound on her lower left leg for 6 months. It started as a small scratch that wouldn’t close. Now it’s a 3cm x 4cm shallow ulcer with irregular borders, located just above her ankle. The wound bed has some patchy granulation tissue but also areas of yellow slough (dead tissue). The edges are rolled and indurated (thick/hard). The surrounding skin is discolored—brownish and shiny—from chronic venous insufficiency. Monica has type 2 diabetes (poorly controlled, HbA1c 9.2%), obesity (BMI 38), and chronic venous insufficiency. Her legs swell by the end of the day. She’s been treating it at home with antibiotic ointment and Band-Aids, but it’s not getting better. “It doesn’t even hurt that much, which worries me. Shouldn’t it hurt?”

What’s Happening:

Monica’s wound is stuck in the inflammatory phase. Multiple factors are preventing progression to proliferation: Diabetes has damaged her small blood vessels (microangiopathy) and nerves (neuropathy). The neuropathy explains why it doesn’t hurt much—she has reduced sensation. The microangiopathy means inadequate oxygen and nutrient delivery to the wound—fibroblasts can’t make collagenA structural protein in the dermis that provides strength and elasticity., keratinocytes can’t migrate. Chronic venous insufficiency means blood pools in her legs instead of returning to the heart efficiently, causing edemaExcess fluid in interstitial spaces. and tissue hypoxiaA deficiency of oxygen in the tissues.. Bacterial biofilm (established community of bacteria) in the wound is keeping neutrophils and macrophages busy fighting infection instead of moving on to proliferation. This wound will NOT heal without addressing these underlying issues.

Comparison to David (Acute Burn):

Monica’s wound is chronic (6+ months, stuck in inflammatory phase); David’s is acute (healing progressed normally through all phases in weeks). Monica has compromised vasculature from diabetes and venous disease; David has intact deeper vessels. Monica has multiple barriers to healing (hyperglycemia, neuropathy, edema, biofilm); David had only the acute injury with no comorbidities. Monica’s treatment is complex, addressing systemic issues; David’s was straightforward local wound care.

Diagnostic Tests:

• Ankle-brachial index (ABI): Measures arterial blood flow to legs. Monica’s is 0.9 (low-normal), indicating some arterial insufficiency—not severe enough to prohibit compression, but suboptimal perfusion.
• Venous duplex ultrasound: Confirms chronic venous insufficiency with incompetent valves—blood is flowing backward, pooling in legs.
• HbA1c: 9.2% (very poorly controlled diabetes; goal is <7%)
• Wound culture: Grows mixed flora including Staphylococcus aureus and Pseudomonas—confirms bacterial burden
• X-ray of ankle: Rules out osteomyelitis (bone infection)—negative

Treatment Journey:

Month 1-2 (Addressing Barriers to Healing):

1. Glucose control: Monica meets with endocrinology. Her oral diabetes medications are adjusted (metformin increased, SGLT2 inhibitor added). She starts working with a dietitian. Goal: Get HbA1c down to 7%.
2. Debridement: At wound clinic every 1-2 weeks, healthcare provider uses sharp debridementThe removal of dead or damaged tissue, commonly performed on burn patients. to remove yellow slough and unhealthy tissue, exposing healthier wound bed.
3. Infection control: Oral antibiotics (doxycycline) for 2 weeks to reduce bacterial burden. Topical antimicrobial dressings (silver or cadexomer iodine foam).
4. Edema control: Prescribed compression therapy—graduated compression stockings (20-30 mmHg) worn daily. This improves venous return, reduces edema, and improves tissue oxygenation. Monica is also instructed to elevate legs above heart level for 30 minutes 3-4 times daily.
5. Offloading: Monica is fitted for special shoes/orthotics to reduce pressure on the ulcer when walking.

Month 3-4 (Signs of Progress): Monica’s HbA1c drops to 7.8%—not perfect, but improving. Her edema is significantly better with compression. The wound bed now has consistent pink granulation tissue—finally, she’s moved from inflammatory to early proliferative phase The phase when the endometrium rebuilds after menstruation.! The wound has decreased in size from 12 cm² to 8 cm². Re-epithelialization is starting from the edges.

Month 5-6 (Advanced Treatments): Progress has slowed. The wound is stuck at about 6 cm². Provider applies cellular/collagen-based wound dressing (like Apligraf or dermal substitute) to provide growthAn increase in size and number of cells. factors and scaffolding for cell migration. Monica also starts negative pressure wound therapy (wound vac)—a sealed dressing connected to a portable pump that applies gentle suction. This removes excess fluid, increases blood flow, and promotes granulation tissue formation.

Month 7-9 (Healing Accelerates): With better glucoseA simple sugar that is the main source of energy for cells. control (HbA1c now 7.2%), consistent compression, wound vac, and advanced dressings, the wound shrinks to 2 cm². Re-epithelialization is progressing steadily from the edges. Monica is seeing a vascular surgeon to discuss possible venous ablation (procedure to close incompetent veinsBlood vessels that return deoxygenated blood to the heart (except pulmonary veins, which carry oxyge) to prevent future ulcers.

Month 10: The wound is CLOSED! Completely re-epithelialized. The new skin is thin, shiny, and fragile. Monica is instructed to continue compression stockings indefinitely, protect the healed area, and monitor for any new breakdown.

Emotional and Lifestyle Impact:

Monica felt “broken and helpless” watching the wound not heal for months. “I thought I was just lazy or doing something wrong. I didn’t realize my diabetes and circulation were preventing healing.” The wound limited her mobility—walking was uncomfortable, and the dressings/wound vac were cumbersome. She felt embarrassed about the odor from the infected wound. “I stopped going to family gatherings because I was self-conscious.”

Treatment required major lifestyle changes: stricter diabetes management, daily compression stockings (hot and uncomfortable), frequent clinic visits, wearing a wound vac for weeks. “It was exhausting, but I finally understood this wouldn’t heal on its own. I had to fix the underlying problems.”

Seeing the wound finally close after 10 months was emotional. “I cried at the clinic. I never thought I’d see normal skin there again.”

Long-term Management:

Monica is at very high risk for recurrence. She must maintain glucose control, wear compression stockings daily for life, inspect her feet and legs daily (the neuropathy means she might not feel new injuries), keep skin moisturized (dry skin cracks more easily), and see her vascular surgeon regularly. She understands now: “This isn’t just a wound. It’s a symptom of bigger problems—my diabetes and circulation. If I don’t manage those, I’ll be back here with another ulcer.”

---